Purpuric exanthema in a patient with hairy cell leukemia treated with cladribine and allopurinol

Ann Hematol. 2017 Jul;96(7):1209-1210. doi: 10.1007/s00277-017-2992-z. Epub 2017 Apr 8.

Authors

Pablo Espinosa Lara¹, Virginia Quirós Redondo², Marta Aguado Lobo³, José Jiménez-Reyes³

Affiliations

¹ Skin Cancer and Cutaneous Toxicities of Cancer Therapy Unit, Department of Dermatology, Hospital Universitario Infanta Cristina, Av. 9 de Junio, 2, Parla, 28981, Madrid, Spain. espinosapab@gmail.com.
² Department of Hematology, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain.
³ Department of Dermatology, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain.

PMID: 28391438
DOI: 10.1007/s00277-017-2992-z

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Allopurinol / adverse effects*
Allopurinol / therapeutic use
Antimetabolites, Antineoplastic / adverse effects
Antimetabolites, Antineoplastic / therapeutic use
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Cladribine / adverse effects*
Cladribine / therapeutic use
Drug Eruptions / physiopathology*
Drug Eruptions / prevention & control
Drug Monitoring
Exanthema / chemically induced*
Exanthema / physiopathology
Exanthema / prevention & control
Humans
Leukemia, Hairy Cell / drug therapy*
Male
Pigmentation Disorders / chemically induced*
Pigmentation Disorders / drug therapy*
Pigmentation Disorders / physiopathology
Pigmentation Disorders / prevention & control
Purpura / chemically induced*
Purpura / drug therapy*
Purpura / physiopathology
Purpura / prevention & control
Severity of Illness Index
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Antineoplastic Agents
Cladribine
Allopurinol

Supplementary concepts

Pigmented purpuric eruption